Table 2 Clinicopathologic characteristics of the 238 BRAF-mutant NSCLC patients
Total (n = 238) | Class 1 (n = 75) | Class 2 (n = 51) | Class 3 (n = 32) | Non-class 1–3 (n = 80) | P-value (1 vs. 2) | P-value (1 vs. 3) | P-value (2 vs. 3) | |
|---|---|---|---|---|---|---|---|---|
Age | 0.87 | 0.70 | 0.75 | |||||
Median (range) | 61 (33–86) | 61 (42–82) | 61 (45–81) | 62 (47–81) | 59 (33–86) | |||
Gender | 0.008 | 0.017 | 1 | |||||
Male | 156 (65.5%) | 38 (50.7%) | 39 (76.5%) | 25 (78.1%) | 54 (67.5%) | |||
Female | 80 (33.6%) | 35 (46.7%) | 12 (23.5%) | 7 (21.9%) | 26 (32.5%) | |||
NA | 2 (0.8%) | 2 (2.7%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
Histology | 0.74 | 0.88 | 0.81 | |||||
Adenocarcinoma | 188 (79.0%) | 60 (80.0%) | 40 (78.4%) | 28 (87.5%) | 60 (75.0%) | |||
Squamous cell carcinoma | 18 (7.6%) | 2 (2.7%) | 3 (5.9%) | 1 (3.1%) | 12 (15.0%) | |||
Adenosquamous carcinoma | 27 (11.3%) | 10 (13.3%) | 7 (13.7%) | 3 (9.4%) | 7 (8.8%) | |||
Large cell carcinoma | 5 (2.1%) | 3 (4.0%) | 1 (2.0%) | 0 (0%) | 1 (1.2%) | |||
Stage | 1 | 1 | 1 | |||||
Stage IA–IIIA | 67 (28.2%) | 20 (26.7%) | 14 (27.5%) | 9 (28.1%) | 24 (30.0%) | |||
Stage IIIB–IVB | 164 (68.9%) | 54 (72.0%) | 35 (68.6%) | 21 (65.6%) | 54 (67.5%) | |||
NA | 7 (2.9%) | 1 (1.3%) | 2 (3.9%) | 2 (6.3%) | 2 (2.5%) | |||
Metastasis | 0.43 | 0.63 | 1 | |||||
M0 | 171 (71.8%) | 55 (73.3%) | 34 (66.7%) | 22 (68.8%) | 60 (75.0%) | |||
M1 | 67 (28.2%) | 20 (26.7%) | 17 (33.3%) | 10 (31.2%) | 20 (25.0%) | |||